다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Neurosurgery, v.47 no.6, 2000년, pp.1391 - 1399
Kaiser, Michael G. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) , Parsa, Andrew T. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) , Fine, Robert L. (Experimental Therapeutics Program, Division of Medical Oncology, College of Physicians and Surgeons of Columbia University, New York, New York) , Hall, Jonathan S. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) , Chakrabarti, Indro (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) , Bruce, Jeffrey N. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of N)
초록이 없습니다.
Semin Hematol Abang 35 Suppl 4 13 1998 The clinical pharmacology of topoisomerase I inhibitors
Semin Hematol Arbuck 35 Suppl 4 3 1998 An overview of topoisomerase I-targeting agents
Neurosurgery Barker 42 709 1998 10.1097/00006123-199804000-00013 Survival and functional status after resection of recurrent glioblastoma multiforme
J Neurooncol Barth 36 91 1998 10.1023/A:1005805203044 Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas
Mol Pharmacol Beidler 47 907 1995 Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity
Hum Gene Ther Beutler 10 95 1999 10.1089/10430349950019228 Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model
Cancer Res Blaney 53 725 1993 Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates
Clin Cancer Res Blaney 4 357 1998 Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study
Cancer Blaney 78 527 1996 10.1002/(SICI)1097-0142(19960801)78:3<527::AID-CNCR21>3.0.CO;2-# Phase II evaluation of topotecan for pediatric central nervous system tumors
Proc Natl Acad Sci U S A Bobo 91 2076 1994 10.1073/pnas.91.6.2076 Convection-enhanced delivery of macromolecules in the brain
J Neurosurg Broaddus 88 734 1998 10.3171/jns.1998.88.4.0734 Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion
Neurosurgery Bruce 46 683 2000 10.1097/00006123-200003000-00031 Intracerebral clysis in a rat glioma model
Oncologist Burris 3 1 1998 10.1634/theoncologist.3-1-1 Topotecan: Incorporating it into the treatment of solid tumors
J Neurosurg Chen 90 315 1999 10.3171/jns.1999.90.2.0315 Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time
J Pharm Biomed Anal Craig 16 199 1997 10.1016/S0731-7085(97)00022-8 Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers
Semin Oncol Dennis 24 Suppl 5 S5-12 1997 An overview of the clinical pharmacology of topotecan
J Neurooncol Farrell 4 403 1987 10.1007/BF00195612 A new glioma model in rat: The C6 spheroid implantation technique permeability and vascular characterization
Cancer Friedman 85 1160 1999 10.1002/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F Topotecan treatment of adults with primary malignant glioma: The Brain Tumor Center at Duke
Anticancer Drugs Goldwasser 10 263 1999 10.1097/00001813-199903000-00002 Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients
Biochemistry Hertzberg 28 4629 1989 10.1021/bi00437a018 On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
Clin Cancer Res Hochster 3 1245 1997 Effect of prolonged topotecan infusion on topoisomerase 1 levels: A phase I and pharmacodynamic study
J Biol Chem Hsiang 260 14873 1985 10.1016/S0021-9258(17)38654-4 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
J Natl Cancer Inst Jain 81 570 1989 10.1093/jnci/81.8.570 Delivery of novel therapeutic agents in tumors: Physiologic barriers and strategies
Neurosurgery Kondziolka 31 280 1992 10.1227/00006123-199208000-00013 Radiobiology of radiosurgery: Part II-The rat C6 glioma model
J Neurosurg Kondziolka 84 1033 1996 10.3171/jns.1996.84.6.1033 Radiosurgery and fractionated radiation therapy: Comparison of different techniques in an in vivo rat glioma model
Neurosurgery Kroll 38 746 1996 10.1227/00006123-199604000-00024 Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor
J Neurosurg Laske 87 586 1997 10.3171/jns.1997.87.4.0586 Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging
Nat Med Laske 3 1362 1997 10.1038/nm1297-1362 Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
J Neurosurg Lieberman 82 1021 1995 10.3171/jns.1995.82.6.1021 Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
J Neurosurg Lonser 89 616 1998 10.3171/jns.1998.89.4.0616 Direct convective delivery of macromolecules to the spinal cord
J Neurosurg Lonser 89 610 1998 10.3171/jns.1998.89.4.0610 Direct convective delivery of macromolecules to peripheral nerves
Ann Oncol Macdonald 7 205 1996 10.1093/oxfordjournals.annonc.a010550 Phase II study of topotecan in patients with recurrent malignant glioma: National Clinical Institute of Canada Clinical Trials Group
Eur J Surg Oncol Mathew 25 321 1999 10.1053/ejso.1998.0650 Survival analysis: Caveats and pitfalls
Am J Physiol Morrison 266 R292 1994 High-flow microinfusion: Tissue penetration and pharmacodynamics
Cancer Chemother Pharmacol 34 S46 1994 10.1007/BF00684863 Clinical, pharmacokinetic and biological studies of topotecan
Neurosurgery Parsa 47 993 2000 10.1097/00006123-200010000-00050 Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy
J Neurooncol Pollina 39 217 1998 10.1023/A:1005954121521 Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model
Lab Anim Sci Redgate 41 269 1991 Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns
Ann Oncol Rothenberg 8 837 1997 10.1023/A:1008270717294 Topoisomerase I inhibitors: Review and update
J Neurosurg Silbergeld 86 525 1997 10.3171/jns.1997.86.3.0525 Isolation and characterization of human malignant glioma cells from histologically normal brain
J Neurooncol Straathof 42 117 1999 10.1023/A:1006166716683 The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration
Int J Cancer Weingart 62 605 1995 10.1002/ijc.2910620519 Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model
Neurochem Res Zirzow 24 301 1999 10.1023/A:1022578424693 Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.